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Abstract
Purpose Dasatinib is a dual Abl/Src tyrosine kinase
inhibitor (TKI) designed as a prototypic short-acting BCR–
ABL-targeted TKI that inhibits BCR–ABL with greater
potency compared with imatinib, nilotinib, bosutinib, and
ponatinib and has been shown to have potential immuno-
modulatory effects. Dasatinib is approved for the treatment
of all phases of chronic myeloid leukemia (CML) and
Philadelphia chromosome-positive acute lymphoblastic
leukemia resistant or intolerant to prior imatinib treatment
and first-line treatment for CML in chronic phase. In this
article, the development of dasatinib as a treatment for
patients with CML is reviewed.
Methods This is a review of the relevant literature
regarding dasatinib development in CML (2003–2013).
Results Dasatinib demonstrates efficacy against most
BCR–ABL mutations arising during imatinib therapy and
is effective in treating patients with imatinib resistance due
to other mechanisms. Randomized trial data show that first-
line dasatinib provides superior responses compared with
imatinib and enables patients to achieve early, deep
responses correlated with improved longer-term outcomes.
Dasatinib has a generally acceptable safety profile, with
most adverse events (AEs) proving manageable and
reversible. Cytopenias are commonly observed with
dasatinib, and some nonhematologic AEs including pleural
effusion have been consistently reported.
Conclusion Dasatinib is an effective treatment option for
patients with CML.
Keywords Dasatinib  Chronic myeloid leukemia 
First-line treatment  Second-line treatment 
Side effects  Early response
Introduction
Chronic myeloid leukemia (CML) is a malignant clonal
disorder of hematopoietic stem cells caused by a chromo-
somal aberration, the Philadelphia (Ph) chromosome,
formed by the chromosomal translocation t(9;22)(q34;
q11). This translocation juxtaposes the ABL gene (chro-
mosome 9) and the BCR gene (chromosome 22), creating a
BCR–ABL fusion gene. The resulting chimeric protein is a
constitutively active ABL tyrosine kinase (Hehlmann et al.
2007). Knowledge of the molecular pathogenesis of CML
has allowed the development of molecular-targeted ther-
apy, which has considerably changed the management and
outcome of patients (Hehlmann et al. 2007; Wong and
Witte 2004). Treatment options for CML include BCR–
ABL tyrosine kinase inhibitors (TKIs), interferon alpha,
chemotherapy, stem cell transplantation, or clinical trials of
novel therapies (Baccarani et al. 2013; NCCN v4. 2013).
Imatinib was the first BCR–ABL inhibitor developed for
CML. Although effective, imatinib is associated with
resistance and/or intolerance that reduce its effectiveness in
a subset of patients who require alternative treatment
options. With first-line imatinib 400 mg once-daily treat-
ment of CML in chronic phase (CML-CP), 65–72 % of
patients achieve a complete cytogenetic response (CCyR)
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and 22–57 % achieve a major molecular response (MMR)
by 12 months (Druker et al. 2006; Hochhaus et al. 2009a;
Hughes et al. 2003; Kantarjian et al. 2010; Saglio et al.
2010a).
Newer BCR–ABL inhibitors (dasatinib, nilotinib, bos-
utinib, and ponatinib) were developed to overcome imati-
nib resistance/intolerance, and most are approved for the
second-line treatment for chronic phase (CP), acceler-
ated phase (AP), or blast phase (BP) CML or Ph? acute
lymphoblastic leukemia (ALL; dasatinib and ponatinib
only) resistant or intolerant to prior imatinib treatment
(nilotinib is not approved for CML-BP). Dasatinib 100 mg
once daily and nilotinib 300 mg twice daily are also
approved as first-line treatment in CML-CP based on
superior efficacy versus imatinib in newly diagnosed
patients (EMA Sprycel [dasatinib] 2012; Kantarjian et al.
2010; Saglio et al. 2010a; Sprycel BMS 2013; Tasigna
Novartis 2013).
Nilotinib and imatinib have similar chemical structures,
with nilotinib showing an improved topographical fit in the
BCR–ABL kinase pocket. Whereas imatinib, nilotinib, and
ponatinib appear to bind only to the inactive conformation
of the kinase, dasatinib is structurally different and binds to
both the inactive and active conformations; bosutinib binds
to the inactive and intermediate state of the protein, and
potentially to the active conformation (Cortes et al. 2010a;
Levinson and Boxer 2012; O’Hare et al. 2005, 2009; Put-
tini et al. 2006; Redaelli et al. 2009; Tokarski et al. 2006;
Vajpai et al. 2008; Weisberg et al. 2005; Zhou et al. 2011).
Dasatinib is a potent multikinase inhibitor targeting
BCR–ABL, the SRC family of kinases (SRC, LCK, HCK,
YES, FYN, FGR, BLK, LYN, FRK), receptor tyrosine
kinases (c-KIT, PDGFR, DDR1 and 2, c-FMS, ephrin
receptors), and TEC family kinases (TEC and BTK) and
demonstrates activity against most imatinib-resistant BCR–
ABL mutations (Branford et al. 2009; Karaman et al. 2008;
Shah et al. 2004). Although immunosuppressive effects
were initially observed in preclinical studies of dasatinib,
recent evidence suggests dasatinib may activate and
mobilize anti-leukemic immune responses, which may
improve efficacy. These immunomodulatory effects may
also be implicated in the clinically relevant side effects
observed with dasatinib treatment (Das et al. 2005; Kre-
utzman et al. 2010, 2011; Mustjoki et al. 2010, 2011, 2013;
Rix et al. 2007). The recommended dose of dasatinib is
100 mg once daily for CML-CP and 140 mg for CML-AP,
CML-BP, or Ph? ALL administered orally, with or with-
out a meal, because effects of food on dasatinib pharma-
cokinetics were not clinically relevant in a study of 54
healthy subjects (EMA Sprycel [dasatinib] 2012; Spry-
cel BMS 2013). Following oral administration, maximum
plasma concentrations of dasatinib are observed between
0.5 and 6 h. Over the dose range of 15–240 mg/day,
dasatinib exhibits dose-proportional increases in the area
under the curve (AUC) and linear elimination characteris-
tics. Overall, mean terminal half-life of dasatinib is 3–5 h
(Sprycel BMS 2013; Wang et al. 2013).
As the number of first-line treatments for newly diag-
nosed CML-CP continues to expand, it is important to
understand the profile of each therapy in order to select the
most appropriate option for each patient. The effect of
dasatinib’s activity profile (high potency, broad spectrum
kinase inhibition, potential immune activity) on efficacy
and side effect profile in patients with CML-CP will be
reviewed in this article.
In vitro development of dasatinib
Dasatinib was discovered by and named after Jagabandhu
Das (Das et al. 2006) as part of an effort to develop potent
inhibitors of Src family kinases (SFKs). Kinase selectivity
panel screening of dasatinib’s parent compound demon-
strated its potency against BCR–ABL and other kinases.
Dasatinib was selected for further development based on its
activity in a xenograft model of CML and favorable
pharmacokinetic profile following oral dosing (Lombardo
et al. 2004). Dasatinib is a prototypic short-acting BCR–
ABL-targeted TKI with increased potency (325-fold)
compared with imatinib in inhibiting unmutated BCR–
ABL (Lombardo et al. 2004; O’Hare et al. 2005).
Imatinib resistance is frequently associated with the
acquisition of BCR–ABL point mutations, of which over
100 have been identified (Hochhaus et al. 2011; Quinta´s-
Cardama and Cortes 2009). Dasatinib is active against the
majority of clinically relevant imatinib-resistant BCR–
ABL mutations, in part due to differing binding constraints,
allowing dasatinib to bind more effectively to certain i-
matinib-resistant BCR–ABL mutants (Hochhaus et al.
2011; Tokarski et al. 2006). Although dasatinib, like i-
matinib, binds to the ATP-binding pocket of BCR–ABL, its
binding site only partially overlaps with imatinib-binding
sites. Crystal structures of the inhibitors bound to ABL
show dasatinib has fewer interactions with the P-loop and
interacts less with the activation loop and a-helix compared
with imatinib (Tokarski et al. 2006). Based on in vitro
assays, dasatinib demonstrates little or no activity against
T315I and V299L (IC50 [ 15 nM); low activity (IC50
5–15 nM) against Y253F, E255 K/V, F317L; and,
depending on the study, low activity against G250E,
Q252H, and Y253H (Burgess et al. 2005; O’Hare et al.
2005; Redaelli et al. 2009). Patients treated with second-
line dasatinib after developing a BCR–ABL mutation on
imatinib had markedly reduced response rates (compared
to patients with no mutations) if they had T315I or F317L,
and possibly lower response rates if carrying Q252H,
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E255 K, or E355G (Apperley et al. 2009; Cortes et al.
2007b; Guilhot et al. 2007; Hochhaus et al. 2007; Mu¨ller
et al. 2009; Soverini et al. 2006, Talpaz et al. 2006).
Mutations arising during dasatinib treatment include
T315I/A, F317L/I/C/V, V299L, and G250E (Cortes et al.
2007b; Hochhaus et al. 2012a; Khorashad et al. 2008;
Mu¨ller et al. 2009; Shah et al. 2007; Soverini et al. 2007a,
b, 2009).
Other kinases potently inhibited by dasatinib include
SRC family kinases (SRC, LCK, LYN, YES, FYN, FRK),
receptor tyrosine kinases (KIT, EPHA2, and PDGFRa and
b), and TEC family kinases (TEC and BTK) (Chang et al.
2008; Dewaele et al. 2010; Hantschel et al. 2007; Huang
et al. 2007; Li et al. 2010; Lombardo et al. 2004). The
multikinase activity of dasatinib may have therapeutic
advantages. Pathologic SFK activity may contribute to
BCR–ABL-independent imatinib resistance in CML (Do-
nato et al. 2003; Pene-Dumitrescu and Smithall 2010).
Another mechanism of BCR–ABL-independent imatinib
resistance is mediated by altered expression of drug influx
and efflux proteins, including OCT-1 (White et al. 2007).
As dasatinib is not a substrate of OCT-1, its activity is
unlikely to be affected by OCT-1 overexpression, in con-
trast to imatinib (Hiwase et al. 2008).
Clinical investigations of dasatinib
The evolution of optimal dasatinib dosing: maintaining
clinical efficacy with reduced toxicity
The efficacy of oral dasatinib was first assessed in a phase
I, open-label, dose-escalation study (Table 1). Patients
(n = 84) with various phases of CML or Ph? ALL intol-
erant or resistant to imatinib received oral dasatinib
(15–240 mg/day) once or twice daily in 4-week treatment
cycles (Talpaz et al. 2006). Dasatinib had clinical activity
in all CML phases and Ph? ALL. Complete hematologic
response (CHR) was achieved in 92 % of patients (37/40)
with CML-CP, and major hematologic response (MHR)
was seen in 70 % of patients (31/44) with CML-AP, CML-
BP, or Ph? ALL. The rates of major cytogenetic response
(MCyR) were 45 % (18/40) in patients with CML-CP and
43 % (19/44) in patients with CML-AP, CML-BP, or Ph?
ALL. Of note, imatinib-associated side effects, including
muscle cramps and nausea, were infrequent with dasatinib,
and patients intolerant to imatinib did not have recurrence
of the same nonhematologic adverse events (AEs) (e.g.,
rash and liver function abnormalities) with dasatinib
treatment. The major AE associated with dasatinib was
Table 1 Efficacy data from the phase I dasatinib dose-escalation
study and phase II START clinical program of second-line dasatinib
in patients with different phases of CML resistant and/or intolerant to
imatinib therapy (Apperley et al. 2009; Kantarjian et al. 2009a; Mauro
et al. 2008; Saglio et al. 2008; Talpaz et al. 2006)
Study/phase Population Follow-up
(months)
Dose schedule N Patients, %




CML-BP, or Ph? ALL
imatinib R/I
Median 12 15 to 240 mg
dasatinib per day
40 (CP) 92 45 35 - - -
11 (AP) 45 27 18 - - -
23 (MBP) 35 35 26 - - -
10 (LBP, Ph?
ALL)
70 80 30 - - -
START-A
phase II




174 45 39 32 - 66 82
START-B
phase II




109 26 34 27 - - 38
START-L
phase II




48 29 52 46 - - 26
START-C
phase II




387 91 62 53 47 80 94
START-R
phase II




101 93 53 44 29 86 -
400 mg imatinib
twice daily
49 82 33 18 12 65 -
AP accelerated phase, BP blast phase, CCyR complete cytogenetic response, CHR complete hematologic response, CP chronic phase, I intol-
erant, L lymphoid, M myeloid, MCyR major cytogenetic response, MMR major molecular response, Ph? ALL Philadelphia chromosome-positive
acute lymphoblastic leukemia, OS overall survival, PFS progression-free survival, R resistant
a START-L also included a Ph? ALL cohort, data not reported here
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reversible myelosuppression. Because dasatinib has a rel-
atively short half-life (3–5 h) (Sprycel BMS 2013; Wang
et al. 2013), the probability of achieving more continuous
BCR–ABL inhibition was thought to be increased by
twice-daily dosing (Shah et al. 2010); however, once-daily
regimens of dasatinib had similar rates of hematologic and
cytogenetic response compared with twice-daily regimens
and lower rates of AEs supported by a recent retrospective
dasatinib exposure–response analysis (Saglio et al. 2010b;
Shah et al. 2008a, 2010; Wang et al. 2013).
A series of phase II trials, the pivotal START (SRC–
ABL Tyrosine kinase inhibition Activity Research Trials)
trial program (Table 1), followed the phase I dose-escala-
tion study. The primary objective for these trials was to
treat patients with resistance or intolerance to imatinib who
therefore had a life-threatening medical need. As the
pharmacokinetics of the dasatinib 70 mg twice-daily regi-
men were better understood, it was selected as the pre-
ferred dosing option in these patients. These open-label,
multicenter trials established the efficacy and safety of
second-line dasatinib (70 mg twice daily) in the treatment
of imatinib-resistant or imatinib-intolerant patients with
CML (all phases) or Ph? ALL. Data from this program led
to the initial approval of dasatinib in these indications.
Two START studies assessed second-line dasatinib
70 mg twice daily in patients with CML-CP. START-C
was a single-arm study, and START-R was a randomized,
parallel-arm study of dasatinib versus high-dose imatinib
(800 mg/day) in patients resistant to standard dose imatinib
(Hochhaus et al. 2007, 2008; Kantarjian et al. 2007, 2009a;
Mauro et al. 2008). In START-C (N = 387), dasatinib
induced MCyR (primary end point) in 62 % of patients
after a minimum follow-up of 24 months (Mauro et al.
2008). The corresponding CCyR rate was 53 %. In
START-R, rates of MCyR were 53 % in the dasatinib
70 mg twice-daily arm (n = 101) and 33 % in the high-
dose imatinib arm (n = 49) (p = 0.017) after a minimum
follow-up of 24 months (Kantarjian et al. 2009a). CCyR
rates were 44 and 18 %, respectively (p = 0.0025).
Although no formal statistical comparison between the
study arms was planned, the data suggested relatively
greater efficacy for dasatinib compared with imatinib
(Kantarjian et al. 2009a). These responses were also
durable, as a pooled analysis (N = 387) of the START-C
and START-R studies showed that 90 % of patients
achieving a CCyR maintained this level of response after
24 months (Baccarani et al. 2008). START-A, START-B,
and START-L were single-arm studies of second-line da-
satinib 70 mg twice daily in patients with CML-AP, CML-
BP, and CML-BP/Ph? ALL, respectively (Apperley et al.
2009; Cortes et al. 2007a, 2008; Guilhot et al. 2007; Ott-
mann et al. 2007; Saglio et al. 2008). In the START-A trial
(N = 174), after a median follow-up of 14.1 months, 64 %
of patients with CML-AP achieved the primary end point
of MHR and 45 % achieved a CHR (Apperley et al. 2009).
START-B included patients with myeloid CML-BP
(N = 109), and START-L included patients with lymphoid
CML-BP (n = 48) and a subset of patients with Ph? ALL
(Cortes et al. 2007a). After a minimum follow-up of
24 months, a CHR was achieved in 26 % of patients with
myeloid CML-BP and in 29 % of patients with lymphoid
CML-BP (Saglio et al. 2008).
The recommended starting dose for dasatinib in patients
with CML-CP is now 100 mg once daily (EMA Sprycel
[dasatinib] 2012; Sprycel BMS 2013) following the
results of a phase III dose-optimization study showing that
100 mg once daily was associated with similar efficacy as
the twice-daily regimen, but with a reduction in toxicity
(Shah et al. 2008a). Although the dasatinib half-life of
3–5 h (Sprycel BMS 2013) was used as a basis for the
initial twice-daily dosing regimen, transient exposure of
CML cell lines to dasatinib in vitro has been demonstrated
to induce apoptosis (Shah et al. 2008b), supporting the
feasibility of once-daily dosing, and data from the phase I
study suggested that once-daily and twice-daily dose
schedules were associated with similar response rates
(Talpaz et al. 2006). Furthermore, due to dose reductions in
the START-C and START-R studies, the median total
daily dose delivered to patients approximated 100 mg/day
(Hochhaus et al. 2007; Kantarjian et al. 2007). It was
therefore proposed to compare the 100 mg once-daily dose
with other schedules. In this dose-optimization study,
patients (N = 670) were randomized to receive dasatinib at
100 mg once daily (n = 167), 140 mg once daily
(n = 167), 50 mg twice daily (n = 168), or 70 mg twice
daily (n = 168) (Shah et al. 2008a). After a minimum
follow-up of 2 years, rates of CCyR and MMR were sim-
ilar across the different dosing schedules (CCyR 50–54 %;
MMR 37–38 %) (Shah et al. 2010). In the 100 mg once-
daily arm, the 24-month rates of CCyR and MMR were 50
and 37 %, respectively. Rates of progression-free survival
(PFS), overall survival (OS), and transformation to AP/BP
by 24 months were 80, 91, and 3 %, respectively (Table 2).
The 100 mg once-daily arm was associated with improved
safety. Rates of all-grade pleural effusion (p = 0.049),
grade C3 thrombocytopenia (p = 0.003), all-grade neu-
tropenia (p = 0.034), and all-grade leukocytopenia
(p = 0.017) were significantly lower for patients treated
with dasatinib 100 mg once daily compared with other
schedules (Shah et al. 2010). After a minimum follow-up
of 5 years, PFS, OS, and rates of transformation to AP/BP
were 57, 78, and 5 %, respectively, in the 100 mg once-
daily arm (Shah et al. 2012).
A similar phase III dose-optimization study in patients
with CML-AP (Kantarjian et al. 2009b) and CML-BP
(Saglio et al. 2010b) led to a recommended dasatinib dose
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of 140 mg once daily in these indications (EMA Sprycel
[dasatinib] 2012; Sprycel BMS 2013). Patients were
randomized to receive dasatinib 70 mg twice daily
(n = 159, AP; n = 74, myeloid BP [MBP]; n = 28, lym-
phoid BP [LBP]) or 140 mg once daily (n = 158, AP;
n = 75 MBP; n = 33, LBP). In patients with CML-AP,
similar rates of MHR (68 vs 66 %) and MCyR (43 vs
39 %) were observed in both treatment arms after a median
follow-up of 15 months. Significantly, fewer patients in the
once-daily arm had pleural effusion compared with the
twice-daily arm (p \ 0.001) (Kantarjian et al. 2009b).
After 2 years of follow-up, for patients with myeloid BP,
the MHR rates in both arms were 28 %; for those with
lymphoid BP, the corresponding rates were 42 % in the
once-daily arm and 32 % in the twice-daily arm. AE rates
were suggestive of improved safety for dasatinib 140 mg
once daily (Saglio et al. 2010b).
Early responses to dasatinib 100 mg once daily
in the treatment for newly diagnosed CML-CP
Following the success of second-line dasatinib in treating
patients with CML, trials were performed to assess the
clinical benefit of this agent in the first-line setting. The
rationale for performing first-line studies derives partly
from the observation that earlier responses to therapy are
associated with better outcomes as seen with first-line i-
matinib (de Lavallade et al. 2008; Druker et al. 2006;
Kantarjian et al. 2008; Marin et al. 2008). Similarly, in a
retrospective analysis of patients from the dasatinib
START-C and START-R, and dose-optimization trials,
patients who achieved CCyR at 12 months had a 24-month
PFS rate of 97 % (95 % confidence interval [CI],
93–100 %) compared with 78 % (95 % CI, 72–83 %) for
patients who did not achieve CCyR or MMR at this time
point (Hochhaus et al. 2009b). In exploratory landmark
analyses of the second-line dasatinib dose-optimization
study, patients receiving dasatinib 100 mg once daily with
cytogenetic assessments at 12 months showing achieve-
ment of CCyR had higher PFS after 4-year minimum fol-
low-up compared with patients achieving less than partial
CyR (PCyR) responses (87 vs 45 %) (Shah et al. 2011).
With 5-year follow-up, similar trends were observed for
patients achieving B10 % BCR–ABL levels compared to
patients with [10 % BCR–ABL levels at 3 months (Shah
et al. 2012). These landmark analyses demonstrate the
importance of achieving an early response to improve
patient outcome. Furthermore, dasatinib is more potent than
imatinib, and less susceptible to mechanisms of imatinib
resistance. Therefore, it may be expected to elicit earlier
responses than imatinib with consequently improved long-
term outcomes.
The first trial investigating dasatinib as first-line treat-
ment was a phase II, open-label study (Cortes et al. 2010b).
Patients with newly diagnosed CML-CP were randomized
to receive dasatinib 100 mg once daily (n = 66) or 50 mg
twice daily (n = 33) (Pemmaraju et al. 2011). Because of
results from a phase III multinational randomized study of
first-line dasatinib and trends in favor of the 100 mg once-
daily schedule of dasatinib seen in this study and others,
the 50 mg twice-daily arm of this trial was closed after 66
patients were enrolled, and all subsequent patients were
randomized to the 100 mg once-daily arm. The study
continues enrolling patients in the once-daily arm (Cortes
et al. 2010b; Pemmaraju et al. 2011). After a median fol-
low-up of 29 months, in patients with C3-month follow-up
(n = 87), rates of CCyR and MMR were 95 and 86 %,
respectively. BCR–ABL levels of B0.0032 % (C4.5-log
reduction; MR4.5) were achieved in 67 % of patients.
Responses were achieved rapidly with 94 and 95 % of
patients achieving a CCyR after 6 and 12 months,
respectively. Similarly, MMR rates at 6 and 12 months
were 68 and 73 %, respectively. These data compare
favorably with historic response data for imatinib (Pem-
maraju et al. 2011).
Dasatinib in the first-line setting was further investigated
in the pivotal, open-label, multinational, randomized phase
III trial of Dasatinib versus Imatinib Study in Treatment-
Naı¨ve CML Patients (DASISION) (Kantarjian et al. 2010).
In this study, 519 patients newly diagnosed with CML-CP
were randomized to receive dasatinib 100 mg once daily
(n = 259) or imatinib 400 mg once daily (n = 260) (Fig-
ure 1) (Kantarjian et al. 2010). Efficacy data are shown in
Table 3. The primary end point of this study was confirmed
Table 2 Efficacy data from the CA180-034 phase III dose-optimi-
zation study of second-line dasatinib in patients with CML-CP
resistant or intolerant to imatinib therapy after a minimum follow-up




CHR MCyR CCyR MMR PFSa OS
100 mg once
daily
167 92 63 50 37 80 91
70 mg twice
daily
168 88 61 54 38 76 88
140 mg once
daily
167 87 63 50 38 75 94
50 mg twice
daily
168 92 61 50 38 76 90
CCyR complete cytogenetic response, CHR complete hematologic
response, MCyR major cytogenetic response, MMR major molecular
response, OS overall survival, PFS progression-free survival
a Definition of disease progression: loss of previous CHR or MCyR,
confirmed AP/BP disease, increasing WBC count (recorded by the
investigator as a doubling from the lowest value to [20,000/mm3 or
increases of [50,000/mm3 on 2 assessments C2 weeks apart),
increase in Ph? metaphases by C30 %, or death from any cause
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CCyR (cCCyR; CCyR on two consecutive assessments) by
12 months. For the dasatinib versus imatinib arms, the rate
of cCCyR by 12 months was 77 versus 66 % (p = 0.007),
respectively (Kantarjian et al. 2010). Cumulative CCyR,
MMR, and MR4.5 rates were higher for dasatinib across a
24-month period (p = 0.0002, p \ 0.0001, and p = 0.002,
respectively) (Kantarjian et al. 2012). Responses to dasat-
inib were rapid and prolonged; median times to CCyR were
3.2 and 6.0 months and median times to MMR were 15 and
36 months in the dasatinib and imatinib arms, respectively
(Kantarjian et al. 2012). At 24 months, for dasatinib versus
imatinib, cumulative rates of MMR were 64 versus 46 %
(p \ 0.0001), rates for BCR–ABL B 0.01 % (MR4) were
29 versus 19 % (p = 0.0053), and rates of MR4.5 were 17
versus 8 % (p = 0.0032) (Hochhaus et al. 2012a; Kan-
tarjian et al. 2012). After 2-year follow-up, transformation
to AP/BP throughout study follow-up (including on study
and after discontinuation) occurred in nine patients (3.5 %)
receiving dasatinib and 15 (5.8 %) receiving imatinib
(Hochhaus et al. 2012a; Kantarjian et al. 2012). At 2-year
follow-up, survival data for this study remain immature,
but no difference was observed between dasatinib and i-
matinib for PFS (93.7 and 92.1 %) and OS (95.3 and
95.2 %). A small difference in failure-free survival for
dasatinib versus imatinib was observed (including protocol
defined progression; 91.2 vs 87.8 %) (Hochhaus et al.
2012a; Kantarjian et al. 2012).
In exploratory analyses, achieving an early molecular
response (BCR–ABL levels of B10 %) at 3 months was
associated with lower transformation rates (dasatinib: 1.5 vs
8.1 %; imatinib: 2.6 vs 9.4 %), better long-term outcomes
(24-month PFS: dasatinib, 97 vs 83 %; imatinib, 96 vs
85 %), and improved response (24-month MMR rates: da-
satinib, 76 vs 16 %; imatinib, 66 vs 19 %) in both treatment
arms (Hochhaus et al. 2012b). Deeper levels of response
were achieved earlier with dasatinib compared with imatinib
as equivalent BCR–ABL (international scale [IS]) levels
were achieved 6 months earlier with dasatinib, and a higher
proportion of patients receiving dasatinib achieved BCR–
ABL levels of B10 % at 3 months compared with patients
receiving imatinib (84 vs 64 %) (Hochhaus et al. 2012b;
Saglio et al. 2012). Similar results were found in another
first-line study of dasatinib. Results from exploratory anal-
yses of the dasatinib arm of the SPIRIT 2 trial have been
reported, and after 2 years of follow-up, 91.4 % of patients
receiving dasatinib achieved BCR–ABL levels of B10 % at
3 months (Marin et al. 2012a). Compared with patients who
had [10 % BCR–ABL levels, patients achieving B10 %
BCR–ABL at 3 months had significantly higher 2-year
cumulative rates of CCyR (91.4 vs 58.8 %, p \ 0.001),
MMR (79.8 vs 14.3 %, p \ 0.001), and MR4.5 (45.7 vs 0 %,
p \ 0.001) (Marin et al. 2012a).
In total, 23 % of dasatinib-treated patients and 25 % of
imatinib-treated patients discontinued treatment in DASI-
SION; 5 and 7 % due to study-defined disease progression
(defined as any of the following: doubling of white cell count
to [20 9 109/L in the absence of CHR; loss of CHR;
increase in Ph-positive metaphases to [35 %; transforma-
tion to AP/BP; death from any cause), 3 and 4 % due to
treatment failure, and 7 and 5 % due to drug-related AEs,
respectively (Kantarjian et al. 2012). In patients who dis-
continued treatment, BCR–ABL mutations were found in 10
patients in each arm, with a narrower spectrum of mutations
seen with dasatinib versus imatinib (3 vs 9 different amino
acids affected). Mutations associated with discontinuation in
the dasatinib arm were T315I (n = 7), F317L (n = 2), and
F317I/V299L (n = 1) (Kantarjian et al. 2012).
Similar levels of response have been observed in addi-
tional studies of first-line dasatinib. In the SWOG S0325
phase II study, newly diagnosed patients were randomized
to receive dasatinib 100 mg once daily (n = 123) or i-
matinib 400 mg once daily (n = 123) (Radich et al. 2012).
At 12 months, median reductions in BCR–ABL transcript
levels were greater with dasatinib compared with imatinib
(3.3 vs 2.8 log; p = 0.063), as were the rates of [3-log
BCR–ABL reductions (59 vs 44 %; p = 0.059). Rate of
CCyR was significantly different between the dasatinib and
imatinib arms (84 and 69 %, respectively; p = 0.040),
although cytogenetic responses were only assessed in 53 %
of patients (Radich et al. 2012).
Side effects or adverse events
Since early clinical trials, some AEs have been consistently
reported in patients receiving dasatinib, including
Randomized (n = 519)
Allocated to dasatinib (n = 259)
– Received dasatinib (n = 258)
Allocated to imatinib (n = 260)
– Received imatinib (n = 258)
Excluded (n = 28)
– No longer met inclusion 
 criteria (n = 20)
– Withdrew consent (n = 3)
– Lost to follow-up (n = 1)
– Other reasons (n = 4)
Analyzed (n = 259)
– Discontinued dasatinib (n = 59)
Analyzed (n = 260)
– Discontinued imatinib (n = 64)
Assessed for eligibility (n = 547)
Fig. 1 Study design and patient disposition for the DASISION phase
III trial of dasatinib versus imatinib in newly diagnosed CML-CP
(Kantarjian et al. 2012)
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myelosuppression, fluid retention, pleural effusion, gas-
trointestinal disorders, fatigue, headache, musculoskeletal
disorders, rash, and infection. Some bleeding events have
also been reported. More recently, cases of pulmonary
arterial hypertension (PAH), a sub-category of pulmonary
hypertension (PH) and atypical of classical PAH with at
least partial reversibility upon drug discontinuation, have
been reported in a small number of patients receiving da-
satinib (Dumitrescu et al. 2011; Fang et al. 2012; Galie`
et al. 2009; Hennigs et al. 2011; Mattei et al. 2009;
McLaughlin et al. 2009; Montani et al. 2012; Orlandi et al.
2011; Philibert et al. 2011; Rasheed et al. 2009; Sano et al.
2012). In clinical trials of first-line and second-line dasat-
inib, most AEs occurred within 12–24 months of treatment
and were managed with dose modifications (Kantarjian
et al. 2012; Shah et al. 2012; Sprycel BMS 2013).
In the early phase I, open-label, dose-escalation study,
the major AE was reversible myelosuppression, leading to
dose interruption in 60 % of patients (Talpaz et al. 2006).
Grade 3/4 neutropenia and thrombocytopenia were seen in
45 and 35 % of patients with CML-CP, respectively.
Nonhematologic AEs included diarrhea, nausea, and
peripheral edema. Treatment-related pleural effusion
occurred in 13 % of patients with CML-CP (Talpaz et al.
2006). Rates of AEs in this study may be expected to be
elevated, as some patients received doses of dasatinib
considerably higher than the current recommended dose of
100 mg once daily (range of dasatinib dose received
15–240 mg/day). A maximum tolerated dose was not
determined in this study, and no patient withdrew from
treatment as a result of toxic effects (Talpaz et al. 2006).
In the following START-C phase II trial, in which
patients with CML-CP received second-line dasatinib
70 mg twice daily, 9 % of patients discontinued treatment
because of study drug toxicity after 8 months of follow-up
(Hochhaus et al. 2007). Cytopenias were common (grade
3/4 thrombocytopenia, 47 %; neutropenia, 49 %), but
generally reversible and manageable with dose adjust-
ments. Pleural effusion was observed in 19 % of patients
(grade 3/4 in 3 %) (Hochhaus et al. 2007). Similar results
were seen in the START-R phase II trial of dasatinib
70 mg twice daily (Kantarjian et al. 2007). After a median
follow-up of 15 months, 28 % of patients had discontinued
treatment, 16 % due to study drug intolerance. Cytopenias
were common (grade 3/4 thrombocytopenia, 56 %; neu-
tropenia, 61 %) but reversible, and manageable with dose
modification. Pleural effusion occurred in 17 % of patients
(Kantarjian et al. 2007). Most cases of pleural effusion
observed across the START studies were managed with
temporary dose interruption, diuretics, or pulse steroid
therapy (Apperley et al. 2009; Cortes et al. 2007a; Hoch-
haus et al. 2007; Kantarjian et al. 2007). In the START-C
and START-R trials, patients received dasatinib at 70 mg
twice daily, which is higher than the current recommended
dose for CML-CP (100 mg once daily). It may therefore be
expected that the frequency of AEs and the rate of dis-
continuation due to study drug intolerance might be higher
than expected in these trials compared with patients
receiving the current recommended dose for CML-CP.
A single institution subgroup analysis of 138 patients
treated with dasatinib in the phase I dose-escalation study
and phase II START trials showed that 29 % of patients
with CML-CP developed pleural effusion (Quinta´s-Card-
ama et al. 2007). Patients receiving 100 mg once-daily
dasatinib had a lower incidence of pleural effusion com-
pared with patients receiving 50 or 70 mg twice daily, or
140 mg once daily, while efficacy remained consistent
across all four dosing schedules. Furthermore, a separate
analysis indicated that intermittent dosing of dasatinib at
100 mg per day for 5 days per week, including a weekend
drug holiday where dasatinib was not taken, led to reduc-
tions in the rate and severity of AEs including fluid
retention and pleural effusion, while efficacy and disease
control were maintained (La Rose´e et al. 2013). An
Table 3 Efficacy data from the DASISION phase III trial of first-line dasatinib versus first-line imatinib in patients with newly diagnosed CML-
CP after a minimum follow-up of 2 years (Kantarjian et al. 2012)
Treatment arm n Patients, %
CCyR cCCyR MMR MR4 MR4.5 PFSa FFSb OS
Dasatinib 100 mg once daily 259 86 80 64 29 17 94 91 95
Imatinib 400 mg once daily 260 82 74 46 19 8 92 88 95
AP accelerated phase, cCCyR confirmed CCyR (CCyR on two separate assessments 28 days apart), CCyR complete cytogenetic response, CHR
complete hematologic response, CP chronic phase, FFS failure-free survival, MCyR major cytogenetic response, MMR major molecular
response, MR4 BCR–ABL B0.01 % (C4-log reduction in BCR–ABL levels), MR4.5 BCR–ABL B0.0032 % (C4.5-log reduction in BCR–ABL
levels), OS overall survival, PCyR partial cytogenetic response, PFS progression-free survival
a Definition of disease progression: development of CML-AP/BP, doubling of white blood cell count to [20 9 109/L in the absence of CHR,
loss of CHR, increase in Ph? bone marrow metaphases to [35 %, death from any cause
b Definition of failure: no hematologic response by 3 months, no CHR or cytogenetic response by 6 months, no PCyR by 12 months, or no
CCyR by 18 months, or progression as defined above
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analysis of risk factors for pleural effusion in patients
treated with second-line dasatinib identified prior history of
cardiac disease (p = 0.02), hypertension (p = 0.01), and
twice-daily dosing schedule (p = 0.05) to be associated
with an increased risk of pleural effusion (Quinta´s-Card-
ama et al. 2007). In a separate analysis, older age was the
only baseline characteristic associated with an increased
risk of pleural effusion (Porkka et al. 2010). The devel-
opment of lymphocytosis during dasatinib treatment was
associated with a 1.7-fold increased risk of pleural effusion
(95 % CI, 1.1–2.5) (Porkka et al. 2010).
The second-line, phase III dose-optimization study
indicated that dasatinib 100 mg once daily was associated
with reduced frequency of AEs compared with twice-daily
dosing regimens in patients with CML-CP, while efficacy
was maintained (Porkka et al. 2010; Shah et al. 2008a,
2012). With a minimum follow-up of 6 months, patients
receiving dasatinib 100 mg once daily had lower rates of
pleural effusion and grade 3/4 thrombocytopenia compared
with patients receiving 70 mg twice daily (7 vs 16 % and
22 vs 37 %, respectively) (Shah et al. 2008a). Fewer
patients receiving dasatinib 100 mg once daily required
dose interruptions (51 vs 68 %), dose reductions (30 vs
55 %), or discontinuation (16 vs 23 %) (Shah et al. 2008a).
With a minimum follow-up of 24 months, 14 % of patients
receiving dasatinib 100 mg once daily developed pleural
effusion, compared with 25 % of patients receiving 70 mg
twice daily (Porkka et al. 2010). Improved tolerability of
once-daily dosing may be due to intermittent dasatinib
exposure in comparison with continuous exposure achieved
by twice-daily dosing (Porkka et al. 2010). After a mini-
mum follow-up of 5 years, grade 3/4 hematologic AEs in
the 100 mg once-daily arm included neutropenia (36 %)
and thrombocytopenia (24 %). Any-grade nonhematologic
AEs included headache (33 %), diarrhea (28 %), fatigue
(26 %), and pleural effusion (24 %) (Shah et al. 2012).
Grade 3/4 cytopenias and any-grade nonhematologic AEs
generally first occurred within 12–24 months of treatment
(Shah et al. 2012).
In the first-line setting, similar AEs were observed.
Treatment-related AEs led to the discontinuation of da-
satinib in 7 % of patients (Kantarjian et al. 2012). Grade
3/4 hematologic AEs were relatively common in patients
with CML-CP receiving dasatinib (100 mg once daily) or
imatinib (400 mg once daily) in DASISION, after a mini-
mum follow-up of 24 months (neutropenia: 24 vs 21 %;
thrombocytopenia: 19 vs 11 %; anemia: 11 vs 8 %)
(Kantarjian et al. 2012). Severe biochemical abnormalities
were uncommon with the exception of grade 3/4 hypo-
phosphatemia (dasatinib arm, 7 %; imatinib arm, 25 %)
(Kantarjian et al. 2012). The most common nonhemato-
logic AEs in DASISION (all grades, dasatinib vs imatinib)
were myalgia (22 vs 39 %), diarrhea (19 vs 21 %), pleural
effusion (14 vs 0 %), headache (13 vs 11 %), superficial
edema (11 vs 36 %), rash (11 vs 17 %), and nausea (10 vs
23 %) (Kantarjian et al. 2012). Grade 3/4 nonhematologic
AEs associated with dasatinib were uncommon at 0–2 %
(fluid retention, 2 %; pleural effusion, 1 %; diarrhea,
\1 %; fatigue, \1 %) (Kantarjian et al. 2012). In DASI-
SION, at 1-year follow-up, 26 patients (10 %) had pleural
effusion; all events were grade 1 (2 %) or grade 2 (8 %)
(Kantarjian et al. 2010). By 2-year follow-up, pleural
effusion events had occurred in 37 patients (14.3 %) and
were generally mild-to-moderate in severity (grade 1:
n = 9, 3.5 %; grade 2: n = 26, 10.1 %; grade 3: n = 2,
0.8 %) with no grade 4 events observed. Events were lar-
gely manageable with treatment interruption (n = 30),
dose reduction (n = 19), or the use of diuretics (n = 17) or
corticosteroids (n = 15). Four patients required a thera-
peutic thoracentesis. At 2-year follow-up, five patients
(1.9 %) had discontinued dasatinib due to pleural effusion.
Notably, the occurrence and management of pleural effu-
sion appeared not to affect the efficacy of dasatinib (Kan-
tarjian et al. 2012; Laneuville et al. 2011).
In some patients receiving dasatinib, large granular
lymphocyte (LGL) expansions carrying clonal T-cell
receptor gene arrangements occur resulting in lymphocy-
tosis (Kreutzman et al. 2010). Data from a retrospective
analysis of patients enrolled in DASISION suggested that
dasatinib-treated patients with lymphocytosis had higher
rates of any-grade pleural effusion and lower rates of
myalgias and arthralgias compared with patients without
lymphocytosis (Schiffer et al. 2010a). In a separate analysis
of pooled study data, 31 % of patients with CML-CP had
lymphocytosis, which was associated with a higher rate of
CCyR and longer PFS in patients with advanced disease
(Schiffer et al. 2010b). However, no formal statistical
testing has been reported for either of these analyses. A
subanalysis of DASISION demonstrated no substantial
effects of baseline cardiovascular conditions, other
comorbidities, or use of baseline medications on the side
effects of dasatinib (Guilhot et al. 2010; Khoury et al.
2010; Saglio et al. 2010c).
More recently, rare cases of PAH in patients receiving
dasatinib for CML and Ph? ALL have been reported in the
literature (n = 16) (Dumitrescu et al. 2011; Hennigs et al.
2011; Mattei et al. 2009; Montani et al. 2012; Orlandi et al.
2011; Philibert et al. 2011; Rasheed et al. 2009; Sano et al.
2012). By 2-year follow-up of the phase III DASISION
trial of dasatinib versus imatinib in newly diagnosed CML-
CP, three patients receiving dasatinib developed PH;
however, no cases of PAH diagnosed by right heart cath-
eterization (RHC) were recorded (Kantarjian et al. 2012).
No patient in DASISION discontinued dasatinib therapy
because of PH or PAH (Kantarjian et al. 2012). PAH
observed in patients receiving dasatinib is not typical, as
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this disease is normally progressive, including cases with a
drug-induced etiology which do not reverse on treatment
withdrawal (Galie` et al. 2009; McLaughlin et al. 2009). To
date, however, the typical clinical course for dasatinib-
associated cases of PAH is improvement or complete res-
olution in the majority of cases upon withdrawal of
treatment.
Guidelines for the management of AEs occurring in
patients receiving dasatinib treatment are largely based on
the experience of clinicians treating patients in early clin-
ical trials (Khoury et al. 2009; Quinta´s-Cardama et al.
2008). For most AEs occurring in patients receiving da-
satinib treatment, guidelines recommend dose interruption
or dose reduction (NCCN v4. 2013; Sprycel BMS 2013).
Early studies showed that cytopenias were usually revers-
ible and effectively managed with dose interruption or
reduction, with a minority of cases requiring blood trans-
fusions or hospitalization (Apperley et al. 2009; Brave
et al. 2008; Cortes et al. 2007a, 2008; Guilhot et al. 2007;
Hochhaus et al. 2007; Ottmann et al. 2007; Quinta´s-
Cardama et al. 2009b; Serpa et al. 2010; Shah et al. 2008a).
In one study, cytopenias resolved in 60 % of patients upon
interruption (Talpaz et al. 2006); in another study, perma-
nent discontinuation was required in only 1 % (Brave et al.
2008). If hematologic AEs occur in patients receiving da-
satinib, treatment should be interrupted until the absolute
neutrophil count is C1.0 9 109/L and platelets C50 9 109/
L. Dasatinib can then be resumed at the original dose if
recovery occurs within 7 days or at a reduced dose of
80/50 mg/day if recovery takes longer than 7 days or if the
event was a second/third recurrence. Although not yet
licensed in all regions, growth factor support may also be
useful for managing hematologic AEs (NCCN v4. 2013;
Quinta´s-Cardama et al. 2009b; Shah et al. 2008a; Sprycel
BMS 2013). If a severe nonhematologic AE (grade 3/4)
develops, guidelines indicate that dasatinib be withheld
until resolution or improvement. Treatment can then be
resumed at a reduced dose dependent on initial severity of
the event (NCCN v4. 2013; Sprycel BMS 2013). Early
reports indicate that most nonhematologic AEs, including
neuropathy, dyspnea, elevated liver enzymes, headache,
bone pain, rash, renal failure, cardiac abnormality, infec-
tions, pancreatitis, and diarrhea, were effectively managed
with dose reductions or interruptions (Apperley et al. 2009;
Cortes et al. 2008; Hochhaus et al. 2007; Serpa et al. 2010).
Consistent with reports, guidelines indicate that most
pleural effusion events can be managed through dose
reduction or interruption, and/or corticosteroids and
diuretics, with a minority of cases requiring thoracentesis,
oxygen therapy, or pleurodesis (Brave et al. 2008; Cortes
et al. 2007a, 2008; Guilhot et al. 2007; Hochhaus et al.
2007; Kantarjian et al. 2012; Laneuville et al. 2011; Shah
et al. 2008a; Talpaz et al. 2006). Once resolved, treatment
can be resumed at the same or at a reduced dasatinib dose
depending on event severity. A retrospective analysis of an
intermittent treatment schedule of dasatinib at different
doses demonstrated a reduction in the grade of pleural
effusion and in hematologic toxicity without compromising
efficacy (La Rose´e et al. 2013). Other fluid retention events
can be managed with diuretics and supportive care. To
reduce the risk of PAH, patients should be evaluated for
signs and symptoms of underlying cardiopulmonary dis-
ease before initiating dasatinib treatment. Upon confirma-
tion of a PAH diagnosis based on RHC, guidelines indicate
that dasatinib should be permanently discontinued (NCCN
v4. 2013; Sprycel BMS 2013). PAH may be at least
partially reversible upon treatment discontinuation. For
bleeding events, recommended management steps include
dose interruption and transfusion (Quinta´s-Cardama et al.
2009a; Sprycel BMS 2013). Rash may be managed with
topical or systemic steroids, in addition to dose reduction,
interruption, or discontinuation. Specific supportive medi-
cation is also indicated in case of headache and diarrhea
(NCCN v4. 2013; Sprycel BMS 2013). A subanalysis of
DASISION showed that dose modifications taken to man-
age AEs had no apparent effect on response (Jabbour et al.
2011).
Conclusions
Dasatinib has superior efficacy over imatinib and man-
ageable side effects in first-line and second-line treatment
of patients with CML. The potent, multi-targeted activity
of dasatinib may contribute to the depth and speed of
response achieved with this agent. Dasatinib’s potential
immune activity may play a role in the observed potency
and requires further investigation. These factors may also
play a role in the safety profile and the AEs observed in
patients receiving dasatinib.
In exploratory analyses, a greater proportion of patients
achieved early, deep molecular responses (B10 % BCR–
ABL at 3 months) with dasatinib compared with imatinib.
Earlier, deeper responses with either TKI were associated
with improved response and survival and decreased trans-
formation to AP/BP. With significantly deeper levels of
molecular response achieved at all time points with up to
2-year follow-up in DASISION, more patients receiving
dasatinib versus imatinib may achieve undetectable levels
of BCR–ABL transcripts and a complete molecular
response. Second-generation BCR–ABL inhibitors have
also demonstrated some activity against CML stem cells,
providing support for future investigation into dasatinib in
achieving a molecular cure (Defina et al. 2012; Hiwase
et al. 2010; Mustjoki et al. 2011). A phase II study is
currently investigating whether CML-CP patients with a
J Cancer Res Clin Oncol (2013) 139:1971–1984 1979
123
sustained complete molecular response (12 months;
B0.0032 % or 4.5-log reduction of BCR–ABL transcript
from standardized baseline) on dasatinib maintain unde-
tectable or minimally detectable BCR–ABL residual dis-
ease upon treatment discontinuation (BMS 2013a).
With changing treatment goals supporting earlier, dee-
per responses, it is reasonable to suggest that second-gen-
eration BCR–ABL inhibitors are likely to be used more
frequently as a first-line treatment option in patients with
newly diagnosed disease, dependent on existing patient
comorbidities and BCR–ABL mutation status (if known).
The speed of response achieved with second-generation
BCR–ABL inhibitors may also allow the early identifica-
tion of a subset of patients resistant to BCR–ABL inhibitor
treatment who may benefit from alternate therapy (stem
cell transplant or clinical trials).
The loss of patent exclusivity for imatinib in 2015
(USA) and 2016 (EU) may influence first-line treatment
selection. With this potential for increased use of imatinib,
it will be important to closely monitor patient response to
ensure early milestones are achieved. Data are emerging to
evaluate the potential benefit of a change in treatment for
patients failing to reach certain levels of response (B10 %
BCR–ABL by 3 months) (Hanfstein et al. 2012; Marin
et al. 2012a, b). Based on these retrospective analyses, the
NCCN guidelines recommend, among several proposed
therapies, a change in treatment for patients with [10 %
BCR–ABL at 3 months (NCCN v4. 2013). However, there
is no data yet showing that such an early change in TKI
therapy will improve outcome. A phase II study comparing
dasatinib 100 mg once daily to imatinib standard of care in
patients failing to achieve an optimal response of B10 %
BCR–ABL after 3 months of imatinib 400 mg/day is cur-
rently in progress (BMS 2013b). This study will test the
hypothesis that changing to dasatinib treatment in this
patient population will induce an improved response rate
(primary end point, MMR at 12 months) compared with
continuing imatinib at any dose. Whether this would be
associated with differences in long-term outcomes (event-
free survival, PFS, OS) remains to be proven.
With the growing number of BCR–ABL inhibitors
available for patients with CML-CP and the lack of head-
to-head clinical trials across second-generation BCR–ABL
inhibitors, choosing a treatment requires consideration on a
patient-to-patient basis, and therefore, information regard-
ing the efficacy and use of these agents in the real-world
setting is of increasing interest. An observational 5-year
prospective cohort study (BMS 2013c) has been initiated to
further understand the use of dasatinib, imatinib, and nil-
otinib in patients with newly diagnosed CML-CP including
response, outcomes, treatment adherence, and patient
quality of life. Data are anticipated to provide additional
information to help guide initial treatment selection.
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